Source: PHARMAC
Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its half-day meeting in October 2025.
Applications
CTAC will discuss three applications for different treatments for a type of blood cancer, diffuse large B-cell lymphoma (DLBCL).
Diffuse large B-cell lymphoma is a fast-growing blood cancer that starts in white blood cells.
Polatuzumab vedotin (POLIVY) for the first line treatment of DLBCL
The Committee will discuss an application for polatuzumab vedotin, in combination with rituximab cyclophosphamide doxorubicin and prednisone, for the treatment of people with diffuse large B-cell lymphoma (DLBCL) that has not been treated with other medicines.
Polatuzumab vedotin is a type of targeted cancer treatment called an antibody-drug conjugate. It attaches to a protein found on B cells and delivers a chemotherapy drug directly to those cells.
Application for Polatuzamab vedotin (POLIVY)(external link)
Glofitamab (COLUMVI) for the treatment of relapsed or refractory DLBCL
The Committee will discuss an application for glofitamab, to be used in combination with chemotherapy (gemcitabine and oxaliplatin), for people with DLBCL that has not responded to, or has returned after prior treatments and who are not able to have a stem-cell transplant. This is for second line or later treatment.
Glofitamab is a type of treatment that works by linking together the immune systems T cells and B cells, helping the T cells destroy cancerous B cells. It is given as an infusion.
Application for Glofitamab (COLUMVI) plus gemcitabine and oxaliplatin (GemOx)(external link)
Epcoritamab (EPKINLY) for the treatment of relapsed or refractory DLBCL
The Committee will discuss an application for epcoritamab for people with DLBCL that has not responded to or has returned after prior treatments (third line or later treatment).
Epcoritamab is similar to glofitamab but is given by a subcutaneous injection. These treatments work by linking together the immune systems T cells and B cells, helping the T cells destroy cancerous B cells.
Application for Epcoritamab (EPKINLY)(external link)
Momelotinib (Omijara) for various types of myelofibrosis
The Committee will discuss an application for momelotinib for people with myelofibrosis (MF), a type of blood cancer where the bone marrow (which makes blood cells) stops working properly. It will consider treatment for intermediate or high-risk primary myelofibrosis, post-polycythaemia vera MF or post-essential thrombocythaemia MF, with moderate to severe anaemia.
Momelotinib is a tablet that is swallowed.
Application for Momelotinib (Omjjara)(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.
Find the Advisory Committee membership and records of meetings
